Eikon Therapeutics presented updated Phase 1b data from its TeLuRide-005 trial evaluating EIK1001 in combination with pembrolizumab and chemotherapy for advanced NSCLC at the 2026 ESMO Congress. The trial demonstrated a 63.1% objective response rate (ORR) and 89.2% disease control rate (DCR) across the pooled population, with a safety profile supportive of outpatient administration. The squamous cohort specifically showed a 72.4% ORR and 100% DCR with a median duration of response of 12.9 months.
Eikon Therapeutics presented initial and updated Phase 1/2 clinical data for its PARP1-selective inhibitors (EIK1003, EIK1004) and WRN helicase inhibitor (EIK1005) at the 2026 ESMO Congress. EIK1003 monotherapy showed a 31.3% objective response rate in PARP-naïve patients with HRR-mutated tumors, while EIK1004 and EIK1005 demonstrated favorable safety and tolerability profiles in early dose-escalation cohorts.
“These data strengthen the foundation of our clinical-stage pipeline, with encouraging evidence of activity and tolerability across our selective PARP1 programs. The EIK1003 results support continued development both as monotherapy and in combination with established cancer treatments, while the initial EIK1004 findings support further evaluation of our CNS-penetrant PARP1 inhibitor. The first clinical results for EIK1005, our internally derived WRN helicase inhibitor, mark an important step in translating Eikon’s discovery science into potential new medicines for patients.”
Roy Baynes, M.D., Ph.D., Chief Medical Officer of Eikon